LeukoVantage, Myeloid
Also known as: Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML)
Use
The LeukoVantage Myeloid test evaluates mutations in 48 genes associated with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). It supports diagnosis, prognosis, and disease monitoring by detecting relevant mutations in these neoplasms. The mutational profile can aid in classification of disease when traditional markers such as BCR‑ABL1, JAK2, CALR, CSF3R, and MPL are absent.
Special Instructions
Not provided.
Limitations
Although this next-generation sequencing assay provides sensitive mutation detection with a limit of detection of approximately 5%, including for MLL PCR targets, it has not been specifically validated for assessing minimal residual disease. Results depend on adequate sample quality and quantity.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
2‑5 mL
Minimum Volume
2 mL
Container
Lavender EDTA tube (also sodium heparin green‑top acceptable)
Collection Instructions
Whole blood collected in lavender EDTA or sodium heparin tube; extracted DNA (20‑50 µL of 10 ng/µL in microcentrifuge tube) or fixed pellet accepted; Pathology/Flow Cytometry report required.
Causes for Rejection
Gross hemolysis; clotted blood sample
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 Days (7 Days for sodium heparin whole blood or bone marrow) |
| Refrigerated | 14 Days (7 Days for sodium heparin whole blood or bone marrow; 2 Years for extracted DNA) |
| Frozen | Not acceptable (but indefinite for extracted DNA) |